The Cancer Letter

Inside information on cancer research and drug development

Capitol Hill

With reduced FY24 funding, NCI prepares to make cuts

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Credit: National Cancer Institute, National Institutes of Health

Halfway into fiscal year 2024, NCI officials are crunching numbers, trying to find ways to live with an appropriation that, for the first time since sequestration, reduces the institute’s spending power.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

Funding Opportunities

DoD Ovarian Research Program FY25 anticipated funding opportunities

The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account